2026-10-25
Does not pass
Coherus Oncology does not pass the ethical screen. The binding factor is interest/revenue 16.6%.
NAS100 27,087 +1.72%
S&P 7,401 +0.65%
GOLD $4,073 −1.00%
BTC $75,828 −0.15%
VIX 24.55 −12.88%
latest tape · as of 20:03 UTC
The Screen · Healthcare · Biotechnology
Coherus Oncology Inc
CHRS · NASDAQ · USD · Market cap $156M · 145 employees
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
FAIL · Does not pass the screen0.75 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price0.75 USD at the 5 Nov 2026 close
- Our regime readDistribution, as of 5 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.10)
- Last reviewed5 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: range not available (screen dated 2026-11-05).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.10, read 2026-10-25
- Ethical does not pass the values gate
Price0.75 USD
Ethical score70.0/100
Our investment reviews on this name
2026-11-01Read Distribution0.83-9.8% to today ✓Markdown gives way to Distribution after an 18% slide in 7 days
2026-10-25Read Markdown1.01-25.8% to today ✓Distribution gives way to Markdown first Markdown read since October
2026-10-11Read Distribution1.01-25.8% to today ✓Markdown gives way to Distribution after a 26% slide in 9 days
2026-10-02Read Markdown1.37-45.3% to today ✓Markup gives way to Markdown after a 20% rise in 5 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its distribution label.
Coherus Oncology Inc holds its Distribution at $0.75. Consolidating, no directional conviction, held for 2 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 2 days |
| Price at the screen | $0.75 |
| Valuation | N/A trailing · -1.60 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.99 |
Five Screens, Shown in Full
Does not pass. Interest/revenue 16.6%
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 15.61% | Below 33% | Interest-bearing debt is just 15.6% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 32.22% | Below 33% | Cash held in interest-bearing accounts and securities is 32.2% of assets, under the one-third limit. | Pass |
| Receivables | 41.30% | Below 49% | Money owed to the company is 41.3% of assets, under the 49% limit. | Pass |
| Revenue purity | 16.60% | Below 5% | 16.6% of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Coherus Oncology does not pass the ethical screen. The binding factor is interest/revenue 16.6%.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Coherus Oncology clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 16%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
Follow this verdict
Get an email when CHRS's ethical verdict changes
Today CHRS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
How a fair value is estimated: discounted cash flow (DCF).
The Street's RangeThird-party analyst targets. The average target sits +1,035% from the screen price.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | -1.6x |
| EPS, trailing | -1.25 |
| EPS, forward | -0.63 |
| Revenue growth | +39.5%strong top-line growth |
| Profit margin | -259.4%currently unprofitable |
| Return on equity | -178.4%not currently earning a positive return on equity |
| FCF yield | -102.63% |
| Debt to equity | 0.89moderate, manageable leverage |
| Current ratio | 1.77healthy short-term liquidity |
| Beta | 0.99steadier than the market |
| Short interest, float | 0.16% |
| 52-week range | 0.94 - 2.62 |
| Moat | NONE |
| Market cap | $156M |
| Employees | 145 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeCHRS trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-01
Distribution · changed $0.83
-17.8% Entry 10
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 17.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 71%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it none, with a mean price target of $8.
2026-10-25
Markdown · changed $1.01
-5.6% Entry 9
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bearish. Over the past year the shares are up 71%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it none, with a mean price target of $8.
2026-10-18
Distribution $1.07
+5.9% Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 5.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 71%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it none, with a mean price target of $8.
2026-10-11
Distribution · changed $1.01
-26.3% Entry 7
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 26.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 71%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it none, with a mean price target of $8.
2026-10-02
Markdown · changed $1.37
+20.2% Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 20.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 71%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it none, with a mean price target of $8.
2026-08-25
Markup · changed $1.14
-18.6% Entry 5
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 18.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 71%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it none, with a mean price target of $8.
2026-07-24
Markdown $1.40
+0.0% Entry 4
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 71%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it none, with a mean price target of $8.
2026-07-18
Markdown $1.40
+0.0% Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 71%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it none, with a mean price target of $8.
2026-07-03
Markdown $1.40
+0.0% Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02
Markdown $1.40
Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets Yahoo Finance · 23 Sep 2026
- Coherus to Participate in Upcoming Investor Conferences Yahoo Finance · 31 Aug 2026
- Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights Yahoo Finance · 17 Aug 2026
- Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript Motley Fool · 13 Aug 2026
- Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript Yahoo Finance · 13 Aug 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
ARMPArmata Pharmaceuticals, Inc.
PEPGPepGen Inc
IPHAInnate Pharma S.A.
KZIAKazia Therapeutics Limited ADR
LENZLENZ Therapeutics Inc
MNOVMediciNova, Inc.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $1.95 | -29.5% | · | $705 | -29.5% |
| 2 months | $1.68 | -18.2% | · | $819 | -18.2% |
| 3 months | $1.69 | -18.6% | · | $814 | -18.6% |
| 6 months | $1.43 | -3.9% | · | $962 | -3.9% |
| 1 year | $0.81 | +70.8% | · | $1,708 | +70.8% |
| 2 years | $1.74 | -21.0% | · | $790 | -21.0% |
| 3 years | $5.42 | -74.6% | · | $254 | -74.6% |
| 5 years | $14.50 | -90.5% | · | $95 | -90.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CHRS does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.